This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zhou, H.-M. Articles by Vassalli, J.-D. Search for Related Content PubMed PubMed Citation Articles by Zhou, H.-M. Articles by Vassalli, J.-D.

Overexpression of Plasminogen Activator Inhibitor Type 2 in Basal Keratinocytes Enhances Papilloma Formation in Transgenic Mice¹

Department of Morphology, University of Geneva Medical School, CH-1211 Geneva 4, Switzerland

The serpin plasminogen activator inhibitor (PAI) type 2 is expressed in differentiated epidermal keratinocytes. To explore its role in this tissue, we studied the impact of PAI-2 overexpression on epidermal differentiation and skin carcinogenesis. A mouse PAI-2-encoding transgene was targeted to basal epidermis and hair follicles under the control of the bovine keratin type 5 gene promoter. Two mouse lines were established, one of which strongly expressed the transgene and produced elevated levels of PAI-2 in the epidermis. Although it had no manifest impact on cellularity or differentiation of skin or hair follicles, PAI-2 overexpression rendered the mice highly susceptible to skin carcinogenesis induced by a single application of 7,12-dimethylbenz(a)anthracene (initiation) followed by twice weekly applications of 12-O-tetradecanoylphorbol-13-acetate [TPA (promotion)]. In transgenic mice, papillomas could be observed after 3 weeks of promotion; after 8 weeks, 94% (31 of 33) of transgenic mice had developed readily visible papillomas, whereas only 35% (7 of 20) of control mice (transgene-negative littermates) had barely detectable lesions. After 11 weeks, all but 1 (32 of 33) of the transgenic mice had papillomas as compared with only 65% (13 of 20) of control mice. After 11 weeks of promotion, application of TPA was terminated. In control mice, papillomas regressed and eventually disappeared; in transgenic mice, there was continued growth of papillomas, some of which further progressed to carcinomas. In contrast to massive apoptosis in regressing papillomas of control mice, only a few apoptotic cells were detected in transgenic papillomas after the cessation of TPA application. The effect of PAI-2 on papilloma formation did not appear to involve inhibition of the secreted protease urokinase-type plasminogen activator (uPA): PAI-2 accumulated predominantly in cells, and PAI-2 overexpression failed to alleviate a phenotype induced by uPA secretion, as demonstrated by a double transgenic strategy. In addition, in situ hybridization revealed that uPA mRNA is not expressed concomitantly with PAI-2 in developing papillomas. We conclude that overexpression of PAI-2 promotes the development and progression of epidermal papillomas in a manner that does not involve inhibition of its extracellular target protease, uPA, but appears to be related to an inhibition of apoptosis.

This article has been cited by other articles:

				L. Tonnetti, S. Netzel-Arnett, G. A. Darnell, T. Hayes, M. S. Buzza, I. E. Anglin, A. Suhrbier, and T. M. Antalis SerpinB2 Protection of Retinoblastoma Protein from Calpain Enhances Tumor Cell Survival Cancer Res., July 15, 2008; 68(14): 5648 - 5657. [Abstract] [Full Text] [PDF]

				G. A. Darnell, T. M. Antalis, B. R. Rose, and A. Suhrbier Silencing of Integrated Human Papillomavirus Type 18 Oncogene Transcription in Cells Expressing SerpinB2 J. Virol., April 1, 2005; 79(7): 4246 - 4256. [Abstract] [Full Text] [PDF]

				J. Liu, S. Yin, N. Reddy, C. Spencer, and S. Sheng Bax Mediates the Apoptosis-Sensitizing Effect of Maspin Cancer Res., March 1, 2004; 64(5): 1703 - 1711. [Abstract] [Full Text] [PDF]

				G. A. Darnell, T. M. Antalis, R. W. Johnstone, B. W. Stringer, S. M. Ogbourne, D. Harrich, and A. Suhrbier Inhibition of Retinoblastoma Protein Degradation by Interaction with the Serpin Plasminogen Activator Inhibitor 2 via a Novel Consensus Motif Mol. Cell. Biol., September 15, 2003; 23(18): 6520 - 6532. [Abstract] [Full Text] [PDF]

				H. Yu, F. Maurer, and R. L. Medcalf Plasminogen activator inhibitor type 2: a regulator of monocyte proliferation and differentiation Blood, April 15, 2002; 99(8): 2810 - 2818. [Abstract] [Full Text] [PDF]